NTHL1 and breast cancer: This result indicates that although the measured level of risk associated with potentially pathogenic NTHL1 variants in isolation is below the current threshold for clinical intervention, a proportion of NTHL1 germline variant carriers in the highest PRS quintile reach a clinically actionable level, as has been described for other low-moderate breast cancer genes7–9.